Our findings that surface CD91/LRP-1 is increased in MDMs treated with Tat, as well as following HIV-1 infection, suggested, at first, that this entry pathway is involved in enhanced amastigote uptake by macrophages. The gene discussed is TAT; the disease is HIV-1 infection.